Merck KGaA’s Tepotinib Receives FDA’s Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations

 Merck KGaA’s Tepotinib Receives FDA’s Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations

Merck KGaA’s Tepotinib Receives FDA’s Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations

Shots:

  • The BT designation is based on ongoing VISION study (NCT02864992) assessing Tepotinib in 73 patients with m-NSCLC harboring MET exon 14 skipping alterations detected by liquid biopsy (LBx) or tissue biopsy (TBx) across different lines of treatment
  • The VISION study results: ORR and DOR for LBx identified patients assessed by IRC & investigator (50% & 55.30% and 12.4 & 17.1 mos.); ORR and DOR for TBx identified patients (45.1% & 54.9% and 15.7 & 14.3) respectively
  • Tepotinib is an investigational oral MET inhibitor, also being investigated in the INSIGHT 2 study (NCT03940703) in combination with Osimertinib in EGFR mutated, MET amplified, LA/m-NSCLC having acquired resistance to prior EGFR TKI and has received MHLW’s Sakigake designation in Mar’2018

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post